A carregar...
Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
BACKGROUND. Triplet chemotherapy has demonstrated manageable toxicities and a favorable response rate. The addition of cetuximab to chemotherapy can increase treatment efficacy. We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3233290/ https://ncbi.nlm.nih.gov/pubmed/22016477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0141 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|